Moomoo AI 已提取核心訊息
On January 25, 2024, RedHill Biopharma Ltd., a biopharmaceutical company, was involved in a significant financial event when Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively referred to as the Reporting Persons) filed a Schedule 13G with the SEC. The filing indicated that each of the Reporting Persons may be deemed to have beneficial ownership of 1,250,000 ordinary shares of RedHill Biopharma, which are represented by American Depositary Shares (ADSs) traded on the New York Stock Exchange under the symbol 'SOS'. This ownership represents approximately 4.0% of the company's class of securities. The filing was made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934 and was completed on February 2, 2024. The Reporting Persons have entered into a Joint Filing Agreement, indicating that they will file jointly in accordance with SEC regulations. The shares in question were related to a Securities Purchase Agreement with RedHill Biopharma, and the Reporting Persons have certified that their acquisition of the shares is not for the purpose of changing or influencing the control of the issuer.
On January 25, 2024, RedHill Biopharma Ltd., a biopharmaceutical company, was involved in a significant financial event when Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively referred to as the Reporting Persons) filed a Schedule 13G with the SEC. The filing indicated that each of the Reporting Persons may be deemed to have beneficial ownership of 1,250,000 ordinary shares of RedHill Biopharma, which are represented by American Depositary Shares (ADSs) traded on the New York Stock Exchange under the symbol 'SOS'. This ownership represents approximately 4.0% of the company's class of securities. The filing was made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934 and was completed on February 2, 2024. The Reporting Persons have entered into a Joint Filing Agreement, indicating that they will file jointly in accordance with SEC regulations. The shares in question were related to a Securities Purchase Agreement with RedHill Biopharma, and the Reporting Persons have certified that their acquisition of the shares is not for the purpose of changing or influencing the control of the issuer.
2024年1月25日，生物製藥公司紅山生物製藥有限公司捲入了一起重大財務事件，當時米切爾·科平、丹尼爾·阿舍爾和Intracoastal Capital LLC（統稱爲申報人）向美國證券交易委員會提交了附表13G。該文件顯示，每位申報人可能被視爲擁有RedHill Biopharma12萬股普通股的實益所有權，這些普通股由在紐約證券交易所上市的美國存托股（ADS）代表，股票代碼爲 “SOS”。該所有權約佔公司證券類別的4.0％。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，並於2024年2月2日完成。申報人已簽訂聯合申報協議，表示他們將根據美國證券交易委員會的規定共同申報。有關股票與RedHill Biopharma簽訂的證券購買協議有關，申報人已證明，他們收購股票的目的不是爲了改變或影響發行人的控制權。
2024年1月25日，生物製藥公司紅山生物製藥有限公司捲入了一起重大財務事件，當時米切爾·科平、丹尼爾·阿舍爾和Intracoastal Capital LLC（統稱爲申報人）向美國證券交易委員會提交了附表13G。該文件顯示，每位申報人可能被視爲擁有RedHill Biopharma12萬股普通股的實益所有權，這些普通股由在紐約證券交易所上市的美國存托股（ADS）代表，股票代碼爲 “SOS”。該所有權約佔公司證券類別的4.0％。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，並於2024年2月2日完成。申報人已簽訂聯合申報協議，表示他們將根據美國證券交易委員會的規定共同申報。有關股票與RedHill Biopharma簽訂的證券購買協議有關，申報人已證明，他們收購股票的目的不是爲了改變或影響發行人的控制權。
有用
沒用